These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 28271251)

  • 1. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
    Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
    J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
    Liu X; Wang L; Xing Y; Engel SS; Zeng L; Yao B; Xu W; Chen G; Zhang Y; Zhang R; Liu S; Weng J; Ji Q
    J Diabetes Investig; 2020 Nov; 11(6):1532-1541. PubMed ID: 32304283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
    Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
    J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
    Kim NH; Moon JS; Lee YH; Cho HC; Kwak SH; Lim S; Moon MK; Kim DL; Kim TH; Ko E; Lee J; Kim SG
    Diabetes Obes Metab; 2024 Sep; 26(9):3642-3652. PubMed ID: 38853720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
    Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
    Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.